References of "Neuprez, Audrey"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailAge-standardized quality of life after hip or knee arthoplasty.
Neuprez, Audrey ULg; KURTH, William ULg; THIRION, Thierry ULg et al

in Osteoporosis International (2016, April), 27(Supplement 1), 541-542

Detailed reference viewed: 43 (6 ULg)
Full Text
Peer Reviewed
See detailAssessment and determinants of aesthetic discomfort in hand osteoarthritis
Neuprez, Audrey ULg; Bruyère, Olivier ULg; Dardenne, Nadia ULg et al

in Annals of the Rheumatic Diseases (2015), 74

Detailed reference viewed: 38 (19 ULg)
Full Text
Peer Reviewed
See detailOstéoporose et Médecine Personnalisée
Reginster, Jean-Yves ULg; NEUPREZ, Audrey ULg; LECART, Marie-Paule ULg et al

in Revue Médicale de Liège (2015), 70(5-6), 321-324

Osteoporosis is at the very early stages of the implementation of personalized medicine. However, the development of FRAX®, an algorithm offering the opportunity to calculate, in an individual patient ... [more ▼]

Osteoporosis is at the very early stages of the implementation of personalized medicine. However, the development of FRAX®, an algorithm offering the opportunity to calculate, in an individual patient, his/her 10-year fracture risk improves the decision process on the appropriateness to initiate a pharmacological treatment. This algorithm helps the physician to select drugs which are active on non-vertebral fractures only in high risk patients. Taking into consideration patients’ preferences, when selecting a therapeutic option, will improve long term adherence and subsequently efficacy and efficiency of the treatments. Attempts to define the natural course of osteoporosis or the response to therapy in individual patients by assessing their genetic profile remains, so far, inconclusive. [less ▲]

Detailed reference viewed: 112 (33 ULg)
Full Text
Peer Reviewed
See detailAesthetic discomfort in hand osteoarthritis: results from the LIège Hand Osteoarthritis Cohort (LIHOC)
Neuprez, Audrey ULg; Bruyère, Olivier ULg; MAHEU, E. et al

in Arthritis Research & Therapy (2015), 17

Introduction: The primary complaint of patients with hand osteoarthritis (OA) is frequently the inelegant appearance of their hands. Only one study has been conducted to assess the magnitude of and ... [more ▼]

Introduction: The primary complaint of patients with hand osteoarthritis (OA) is frequently the inelegant appearance of their hands. Only one study has been conducted to assess the magnitude of and identify the determinants of aesthetic discomfort in hand OA. Methods: The LIège Hand Osteoarthritis Cohort is a prospective cohort of 203 patients diagnosed with hand OA. At baseline, these patients rated their aesthetic discomfort on a 100-mm visual analogue scale (VAS) and used a Likert scale (range 0–7) to quantify the magnitude of their aesthetic damage. Results: The median value of the aesthetic discomfort VAS was 35.0 [interquartile range (Q1–Q3) 6.0–59.0]. The median damage was rated 3.0 (Q1–Q3 1.0–4.0), corresponding to a moderate level. Both were significantly (p < 0.02) associated with the female gender, the duration of hand OA, the radiological severity of OA (Verbruggen–Veys and Kellgren–Lawrence scales) and pain, disability, or stiffness [Australian Canadian Osteoarthritis Hand Index (AUSCAN) and Functional Index for Hand Osteoarthritis ]. After a stepwise analysis, the parameters correlated to the aesthetic discomfort were the presence of erosive joints (p = 0.0048), the AUSCAN score (p < 0.0001), the number of joints with severe radiological damage (p = 0.023), and gender (p = 0.0009). For aesthetic damage, the parameters associated were AUSCAN score (p < 0.0001), duration of hand OA >10 years (p = 0.001), and presence of erosive joints (p < 0.0001). Compared with patients with low aesthetic discomfort (VAS ≤33 mm), those with the highest discomfort (VAS ≥66 mm) had more erosive OA (p = 0.014), a higher Verbruggen and Veys score (p = 0.0039), and a higher AUSCAN score (p < 0.001). Conclusions: Aesthetic discomfort and damage are significant complaints in patients with hand OA. The determinants of the magnitude of these are gender, radiological severity, duration of hand OA, presence of erosive joints, and impact on pain, function, and stiffness as assessed with the AUSCAN. [less ▲]

Detailed reference viewed: 25 (7 ULg)
Full Text
Peer Reviewed
See detailDevelopment and validation of the French version of a tool assessing patient's expectations in lower limb osteoarthritis
NEUPREZ, Audrey ULg; Delcour, Jean-Pierre; Fatemi, Firouzeh et al

in Journal of Orthopaedics (2015), 12

Objective: The Hospital for Special Surgery (HSS) Hip Replacement Expectations Survey and <br />Knee Replacement Expectations Survey are validated tools developed to measure patients' <br />preoperative ... [more ▼]

Objective: The Hospital for Special Surgery (HSS) Hip Replacement Expectations Survey and <br />Knee Replacement Expectations Survey are validated tools developed to measure patients' <br />preoperative expectations for hip and knee arthroplasty. These instruments have possible <br />uses in both daily practice and research. Our objective was to assess the test-retest reliability <br />and the construct validity of the French version of the surveys. <br />Methods: Patients scheduled for total hip (n ¼ 82) or knee replacement (n ¼ 61) aged 38e90 <br />years were included. All completed the HSS Hip or Knee Replacement Expectations Survey <br />and the Expectation WOMAC to determine concurrent validity. <br />The test-retest reliability was assessed using the intraclass coefficient correlation (ICC), <br />the Bland and Altman Method and the coefficient of variation; the internal consistency was <br />assessed by the Cronbach a coefficient. The construct validity was investigated using the <br />Pearson correlation coefficient and floor and ceiling effects by percentage frequency of <br />lowest or highest possible score achieved by respondents. <br />Results: 143 patients scheduled for hip or knee arthroplasty were included. <br />The reliability was excellent between the test and the rested total score, with an ICC of <br />0.902 (0.853e0.936) and CV of 4.06% for the French Hip Replacement Expectations Survey <br />and 0.865 (0.786e0.917) and CV of 7.7% for the French Knee Replacement Expectations <br />Survey, without bias. <br />The Cronbach a coefficient was 0.72 for hip Survey and 0.82 for knee Survey showing a <br />good internal consistency. <br />Pearson correlation coefficients of 0.45 and 0.48 between Expectations WOMAC and <br />HSS, respectively for hip Survey and knee Survey, were observed but with systematic bias. <br />The lowest possible score was not reported by any patient and only three patients <br />(3.66%) scheduled for hip arthroplasty reported the highest possible score. Conclusions: The French version of the HSS Hip or Knee Replacement Expectations Survey is <br />a reliable and valid questionnaire and compares favourably with the original English <br />version. Therefore, this new version may help French-speaking clinicians to evaluate expectations <br />before lower limb arthroplasty. [less ▲]

Detailed reference viewed: 105 (44 ULg)
Full Text
Peer Reviewed
See detailBaseline characteristics of the Liège Hand Osteoarthritis Cohort (LIHOC)
NEUPREZ, Audrey ULg; Bruyère, Olivier ULg; Dardenne, Nadia ULg et al

in Annals of the Rheumatic Diseases (2015), 74(Supp2), 1346

Detailed reference viewed: 26 (8 ULg)
Full Text
Peer Reviewed
See detailBaseline characteristics of the Liège hand osteoarthritis cohort (LIHOC)
Neuprez, Audrey ULg; Bruyère, Olivier ULg; Dardenne, Nadia ULg et al

in Osteoporosis International (2015), 26(S1), 167

Detailed reference viewed: 20 (10 ULg)
Full Text
Peer Reviewed
See detailEfficacy and safety of currently marketed anti-osteoporosis medications
Reginster, Jean-Yves ULg; NEUPREZ, Audrey ULg; Dardenne, Nadia ULg et al

in Best Practice & Research. Clinical Endocrinology & Metabolism (2014), 28

During the past 2 decades, many interventions were proven effective in the management of postmenopausal osteoporosis. The objective of an anti-osteoporosis treatment is to reduce fracture rates, ideally ... [more ▼]

During the past 2 decades, many interventions were proven effective in the management of postmenopausal osteoporosis. The objective of an anti-osteoporosis treatment is to reduce fracture rates, ideally at all skeletal sites (i.e. spine, hip, and other non-spine). The armamentarium against osteoporosis includes anti-resorptive agents (i.e. bisphosphonates, selective estrogen receptor modulators and denosumab), bone-forming agents (i.e. peptides from the parathyroid hormone family) and one agent with a dual mechanism of action (i.e. strontium ranelate). All these medications combine anti-fracture efficacy with a reasonable benefit/risk profile. However, the choice of a particular chemical entity, in one individual patient is based on the knowledge and expertise of the physician. Prioritization of drugs should be based on the individual profile of the patient, the severity of osteoporosis and the specific contraindications, warnings and precautions of use of the various available medications. [less ▲]

Detailed reference viewed: 46 (15 ULg)
Full Text
Peer Reviewed
See detailQuality of life benefits of knee arthroplasty for osteoarthritis
NEUPREZ, Audrey ULg; François, Garance ULg; KURTH, William ULg et al

in Osteoporosis International (2014), 25(2), 40

Detailed reference viewed: 60 (9 ULg)
Full Text
Peer Reviewed
See detailOsteonecrosis of the jaw in a male osteoporotic patient treated with denosumab
NEUPREZ, Audrey ULg; Coste, S; Rompen, Eric ULg et al

in Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA (2014), 25

Osteonecrosis of the jaw (ONJ) is a clinical condition associated with long-term exposure to inhibitors of bone resorption, mainly bisphosphonates. Denosumab (DMab) is a human monoclonal antibody of the ... [more ▼]

Osteonecrosis of the jaw (ONJ) is a clinical condition associated with long-term exposure to inhibitors of bone resorption, mainly bisphosphonates. Denosumab (DMab) is a human monoclonal antibody of the receptor activator of nuclear factor kappa-B ligand. It prevents osteoclast-mediated bone resorption and is widely prescribed for the management of postmenopausal osteoporosis. Whereas ONJ has already been reported in women treated with DMab, we report for the first time the development of ONJ, following tooth extraction, in a male patient treated for idiopathic osteoporosis with DMab. Due to the constant increase in DMab prescription, for the management of osteoporosis, in both genders, physicians should be made aware of this potential risk. [less ▲]

Detailed reference viewed: 56 (15 ULg)
Full Text
Peer Reviewed
See detailRisk of hip fracture in community-dwelling and institutionalized osteoporotic patients: A 3-year study.
Bruyère, Olivier ULg; Hiligsmann, Mickaël ULg; Zegels, Brigitte ULg et al

in International Journal of Gerontology (2013), 7(3), 167-70

Background and aims: It has been previously suggested that the incidence of hip fracture is higher among <br />people living in nursing homes than among community-dwelling people. However, it is not clear ... [more ▼]

Background and aims: It has been previously suggested that the incidence of hip fracture is higher among <br />people living in nursing homes than among community-dwelling people. However, it is not clear <br />whether this is a consequence of nursing home residency or of the greater age of the residents. We have <br />examined the relationship between the place of residence and hip fracture incidence, in a prospective 3- <br />year study. <br />Methods: Women from nine countries included in this study were part of the placebo group of <br />a randomized controlled trial having assessed the long-term effect of a new antiosteoporotic drug. All <br />women were osteoporotic and received placebo and vitamin D during the 3 years of follow-up. All the <br />institutionalized (nursing home, medical house) women (n ¼ 217) were included in this post hoc analysis <br />and three noninstitutionalized age- and country-matched controls were included (n ¼ 651). <br />Results: The mean (and standard deviation) age of the patients was 80.4 (5.6) years in the institutionalized <br />women and 80.2 (5.8) years in the noninstitutionalized women (p ¼ 0.87). After 3 years of followup, <br />37 fractures occurred: 12 (5.5%) in institutionalized women and 25 (3.8%) in noninstitutionalized <br />women. The difference between the two groups was not statistically significant (p ¼ 0.29). After <br />controlling for age, body mass index, femoral neck bone mineral density and prevalent nonvertebral <br />fracture, the residence status of the patient (institutionalized vs. noninstitutionalized) was not significantly <br />associated with hip fracture incidence (p ¼ 0.63). <br />Conclusions: We suggest that living in an institutionalized place is not an independent risk factor for hip <br />fracture for osteoporotic women receiving calcium and vitamin D. [less ▲]

Detailed reference viewed: 71 (25 ULg)
Full Text
Peer Reviewed
See detailComparison of the proportion of patients potentially treated with an anti-osteoporotic drug using the current criteria of the Belgian national social security and the new suggested FRAX criteria
Bruyère, Olivier ULg; Fossi, Martin; Zegels, Brigitte ULg et al

in Rheumatology International (2013), 33(4), 973-8

To assess the number of anti-osteoporosis treatments that would be reimbursed by the Belgian social security if either FRAX or the current criteria were used to determine access to reimbursement. This is ... [more ▼]

To assess the number of anti-osteoporosis treatments that would be reimbursed by the Belgian social security if either FRAX or the current criteria were used to determine access to reimbursement. This is a retrospective study based on data from 1,000 women randomly selected from an outpatient hospital specialized in bone metabolism in Belgium. Proportions of potentially refunded treatments between FRAX and current criteria were compared. Out of the 1,000 women files, 890 have sufficient information to assess FRAX . In Belgium, current criteria include a bone mineral density (BMD) T score below -2.5 at the lumbar spine, the femoral neck or the total hip and/or at least a prevalent vertebral fracture. Using these criteria, 167 women (18.8 %) would have access to reimbursement. Using the criteria based on the validated Belgian FRAX tool, only 116 women (13.0 %) would have access to reimbursement, meaning that access to reimbursement based on FRAX criteria would reduce by 30 % the anti-osteoporosis drug expenses covered by the national social security. Interestingly, only 65 women out of the 116 (56.0 %) selected with the FRAX criteria were also selected with the current criteria of the national social security. A substantial proportion of individuals that would potentially receive a reimbursement for their treatment using the FRAX criteria do not have access to any refund for their treatment with the current criteria. Since patients identified with the FRAX tool are those with the highest risk profile for future fractures, reappraisals of treatment reimbursement guidelines are expected in Belgium. [less ▲]

Detailed reference viewed: 42 (22 ULg)
Full Text
Peer Reviewed
See detailValidity of the French hip and knee replacement expectations surveys
NEUPREZ, Audrey ULg; François, Garance ULg; Delcour, JP et al

in Osteoporosis International (2013, April), 24(Suppl.1), 374

Detailed reference viewed: 45 (21 ULg)
Full Text
Peer Reviewed
See detailDéveloppement et validation de la version française d'un questionnaire traitant des attentes des patients dans l'arthrose des membres inférieurs
NEUPREZ, Audrey ULg; Delcour, JP; Fatemi, F et al

in Revue du Rhumatisme (2013), 80(S1), 181

Detailed reference viewed: 63 (9 ULg)
Peer Reviewed
See detailUsefulness of electrophysiology in muscle channelopathies
BETHLEN, Sarah ULg; NEUPREZ, Audrey ULg; Maystadt, Isabelle et al

Conference (2012, November 22)

Detailed reference viewed: 52 (8 ULg)
Full Text
Peer Reviewed
See detailRole of glucosamine in the treatment for osteoarthritis.
REGINSTER, Jean-Yves ULg; Neuprez, Audrey ULg; LECART, Marie-Paule ULg et al

in Rheumatology International (2012), 32(10), 2959-67

Over the last 20 years, several studies have investigated the ability of glucosamine sulfate to improve the symptoms (pain and function) and to delay the structural progression of osteoarthritis. There is ... [more ▼]

Over the last 20 years, several studies have investigated the ability of glucosamine sulfate to improve the symptoms (pain and function) and to delay the structural progression of osteoarthritis. There is now a large, convergent body of evidence that glucosamine sulfate, given at a daily oral dose of 1,500 mg, is able to significantly reduce the symptoms of osteoarthritis in the lower limbs. This dose of glucosamine sulfate has also been shown, in two independent studies, to prevent the joint space narrowing observed at the femorotibial compartment in patients with mild-to-moderate knee osteoarthritis. This effect also translated into a 50 % reduction in the incidence of osteoarthritis-related surgery of the lower limbs during a 5-year period following the withdrawal of the treatment. Some discrepancies have been described between the results of studies performed with a patent-protected formulation of glucosamine sulfate distributed as a drug and those having used glucosamine preparations purchased from global suppliers, packaged, and sold over-the-counter as nutritional supplements. [less ▲]

Detailed reference viewed: 80 (25 ULg)